News | April 01, 2025
Briefs: AstraZeneca Pharma India, Pharmaids and Dr. Agarwal's Health Care
AstraZeneca Pharma India discontinues manufacturing of Imdur
AstraZeneca Pharma India discontinues manufacturing of Imdur
Wipro’s agents for Agentforce will elevate efficiency and customer satisfaction at healthcare companies
This addition strengthens Dr. Agarwals Eye Hospital's vast network of 28 hospitals across Karnataka and 220+ facilities worldwide
Zydus will carry out early-stage development, animal immunogenicity studies and regulatory preclinical toxicology studies for this combination vaccine
Standalone profit from operations for Q4-2024 were Rs. 108 crore
Eleven CRDMOs collaborate to form IPSO with the aim to elevate India’s position in the global pharmaceutical value-chain
Zongertinib would be the first orally administered, targeted therapy for previously treated patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC), if approved
Innovative chronic pain treatment receives IP protection in India's $55 billion pharmaceutical market
Total Income during Q3 FY25 stood at Rs. 527.37 crore as compared to Rs. 528.77 crore in Q3 FY24
Peter Bains has over three decades of experience in the biotech and pharmaceutical industry
Subscribe To Our Newsletter & Stay Updated
